5K7K

Design and Optimization of Biaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7: Discovery of Clinical Candidate PF-05089771


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.3 Å
  • R-Value Free: 0.272 
  • R-Value Work: 0.224 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.

Swain, N.A.Batchelor, D.Beaudoin, S.Bechle, B.M.Bradley, P.A.Brown, A.D.Brown, B.Butcher, K.J.Butt, R.P.Chapman, M.L.Denton, S.Ellis, D.Galan, S.R.G.Gaulier, S.M.Greener, B.S.de Groot, M.J.Glossop, M.S.Gurrell, I.K.Hannam, J.Johnson, M.S.Lin, Z.Markworth, C.J.Marron, B.E.Millan, D.S.Nakagawa, S.Pike, A.Printzenhoff, D.Rawson, D.J.Ransley, S.J.Reister, S.M.Sasaki, K.Storer, R.I.Stupple, P.A.West, C.W.

(2017) J. Med. Chem. 60: 7029-7042

  • DOI: 10.1021/acs.jmedchem.7b00598

  • PubMed Abstract: 
  • A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective Na <sub>V </sub>1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and ...

    A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective Na V 1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction concerns to deliver the desired balance of preclinical in vitro properties. Concerns over nonmetabolic routes of clearance, variable clearance in preclinical species, and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clinical pharmacokinetics. The design strategies and results from preclinical PK and clinical human microdose PK data are described leading to the discovery of the first subtype selective Na V 1.7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage sensing domain.


    Organizational Affiliation

    Worldwide Medicinal Chemistry, Pfizer Inc. , Eastern Point Road, Groton, Connecticut 06340, United States.,Icagen Inc. , 4222 Emperor Blvd no. 350, Durham, North Carolina 27703, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Cytochrome P450 2C9
A
477Homo sapiensMutation(s): 0 
Gene Names: CYP2C9 (CYP2C10)
EC: 1.14.14.-
Find proteins for P11712 (Homo sapiens)
Go to Gene View: CYP2C9
Go to UniProtKB:  P11712
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
6RJ
Query on 6RJ

Download SDF File 
Download CCD File 
A
4-[4-chloranyl-2-(1~{H}-pyrazol-4-yl)phenoxy]-3-cyano-~{N}-(1,3-thiazol-2-yl)benzenesulfonamide
C19 H12 Cl N5 O3 S2
XPZRWGQUAVWXIG-UHFFFAOYSA-N
 Ligand Interaction
HEM
Query on HEM

Download SDF File 
Download CCD File 
A
PROTOPORPHYRIN IX CONTAINING FE
HEME
C34 H32 Fe N4 O4
KABFMIBPWCXCRK-RGGAHWMASA-L
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
6RJIC50: 36 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.3 Å
  • R-Value Free: 0.272 
  • R-Value Work: 0.224 
  • Space Group: H 3
Unit Cell:
Length (Å)Angle (°)
a = 91.690α = 90.00
b = 91.690β = 90.00
c = 169.880γ = 120.00
Software Package:
Software NamePurpose
HKL-2000data reduction
REFMACrefinement
PHASERphasing
HKL-2000data scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2017-06-07
    Type: Initial release
  • Version 1.1: 2017-08-30
    Type: Database references
  • Version 1.2: 2017-09-06
    Type: Database references